Answers are grounded in this paper and cite their sources.
Carperitide, a recombinant form of alpha-human atrial natriuretic peptide, has been widely used in patients with acute heart failure and pulmonary congestion. Here we report five cases of severe pulmonary edema due to preeclampsia treated with carperitide. Five postpartum patients underwent emergency cesarean section because of maternal organ failure at 30+2 (25+2–34+2) weeks of gestation and were diagnosed with pulmonary edema prior to or immediately after delivery. Carperitide 0.025 (0.023–0.029) μg/kg/min was administrated postpartum for 3 (2–5) days. After treatment, air space opacification improved, and the cardiothoracic ratio significantly decreased from 54.4% (52.0–61.1) to 49.5% (44.7–51.5) (P=0.038), with a decrease in blood pressure and rapid increase in urine output after initiation of carperitide. Dyspnea improved in all patients, with favorable maternal outcomes and no adverse effects attributable to carperitide. Carperitide may effectively alleviate severe pulmonary edema attributed to preeclampsia, thereby potentially enhancing the overall postpartum health status of affected individuals.
No takes yet. Share an insight, caveat, or question.
Toshinari et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: